Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption

Feb. 5, 2010 (PR Newswire) — Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption

SUNNYVALE, Calif. — Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that more than 12,000 courses of lung cancer treatment have been completed with CyberKnife radiosurgery. Usage of CyberKnife radiosurgery for lung cancer continues to grow, as illustrated by a 25 percent increase year over year in calendar year 2009.

CyberKnife radiosurgery offers lung cancer patients a non-invasive means for treating their disease. The outpatient treatment is completed in five or fewer visits, and is both painless and non-surgical. Because the CyberKnife System utilizes continual image guidance along with continual correction for respiratory motion, it is able to deliver high-doses of radiation to the tumor from hundreds of angles with pinpoint precision.

Judith, a lung cancer survivor, shares her experience having been treated with both conventional lung cancer treatments and CyberKnife radiosurgery:

Judith was diagnosed with stage IIIa lung cancer in the winter of 2004. At that time she received 12 rounds chemotherapy, 23 days of radiation therapy and surgery two weeks later to remove the upper lobe of her right lung. Recovery from her treatment was difficult, involving a 15 day hospital stay and four weeks of recovery at home. During a follow-up visit, some residual cancer was discovered leading her to undergo eight more rounds of chemotherapy. Judith hoped the worst of things were behind her and for almost three years they were.

Then in the summer of 2007 doctors found a recurrence of her cancer in a lymph node located deep in the center of Judith’s chest. Since she had already undergone surgery and had received conventional radiation years prior and given the location of the cancer close to sensitive, vital structures in her chest, her thoracic surgeon suggested CyberKnife radiosurgery. Because of its extreme precision, the CyberKnife System is able to focus the radiation delivery on the tumor and avoid surrounding healthy tissue, meaning Judith was a candidate despite having previous radiation. Judith’s CyberKnife treatment was completed in four outpatient sessions. She was able to resume her daily activities after each treatment and got back to work right away. Nearly three years later Judith is doing well and has had no recurrences.

“The first time round, it was an eight month period of my life spent at the cancer center, so the second time, when I had the option to do four treatments over two weeks and be done, it was a no brainer,” said Judith. “With the CyberKnife there was no downtime and I didn’t experience any side effects. During the treatments I just lay comfortably on the treatment table and was able to watch the animal channel on a TV in the ceiling. It was a piece of cake compared to what I had been through already.”

To view a brief interview with Judith, please visit: http://www.youtube.com/cyberknifeckcam.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to deliver more than 80,000 treatments worldwide and currently 190 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10-K for the 2009 fiscal year, our quarterly report on Form 10-Q filed on February 4, 2010 and our other filings with the Securities and Exchange Commission. The Company’s actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.